Publications by authors named "K U Johannes"
Objectives: To compare the precision of two cephalometric landmark identification methods, namely a computer-assisted human examination software and an artificial intelligence program, based on South African data.
Methods: This retrospective quantitative cross-sectional analytical study utilized a data set consisting of 409 cephalograms obtained from a South African population. 19 landmarks were identified in each of the 409 cephalograms by the primary researcher using the two programs [(409 cephalograms x 19 landmarks) x 2 methods = 15,542 landmarks)].
Patients with axial spondyloarthritis (axSpA) suffer from one of the longest diagnostic delays among all rheumatic diseases. Telemedicine (TM) may reduce this diagnostic delay by providing easy access to care. Diagnostic rheumatology telehealth studies are scarce and largely limited to traditional synchronous approaches such as resource-intensive video and telephone consultations.
View Article and Find Full Text PDFThere is a paucity of empirical research on the use of non-pharmacological interventions to both treat and curb the spread of Alzheimer's disease (AD) across the globe. This paper examines the biochemical and clinical outlook and the social implications of the condition in relation to psychological aspects that may indicate a direction for further interventions. There is a scarcity of research on the effectiveness of using various psychological aspects of AD, a disease characterized by a process of transition from health and independence to a dependent state with a progressive loss of memory and functional skills.
View Article and Find Full Text PDFArticle Synopsis
- Vγ9Vδ2 T cell immunotherapy is being explored for its ability to fight various cancers by leveraging its unique cytotoxic properties that don't rely on MHC recognition.
- Researchers have found that the BTN2A1 and BTN3A1 proteins provide the primary activation signal (signal 1) for Vγ9Vδ2 T cells, while the details surrounding the necessary secondary signal (signal 2) needed for full activation remain uncertain.
- In experiments, a BTN2A1/3A1 fusion protein activated Vγ9Vδ2 T cells when combined with costimulatory signals, and it also boosted the cancer-killing ability of these T cells against CD19 lymphoma cells, indicating that tumor cells
Article Synopsis
- Combining TIGIT and PD-1/PD-L1 blockade could enhance cancer treatment effectiveness in patients with high PD-L1 expression and no prior checkpoint therapy.
- TIGIT-Fc-LIGHT fusion proteins stimulate the immune response by activating myeloid cells and enhancing the function of CD8 T and NK cells, potentially overcoming resistance to existing PD-1 therapies.
- The research indicates that LIGHT, as an immune costimulator, may expand the therapeutic benefits of TIGIT blockade in a broader range of tumor types, addressing limitations in treatment for resistant cancers.